Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(54)
•••
Comment by HarveyTwofaceon Sep 09, 2018 5:39am
112 Views
Post# 28585978

RE:RE:ADvices from most-blocked, PoorOpinion!

RE:RE:ADvices from most-blocked, PoorOpinion!PoorOpinion - You obviously don't know what you are talking about. You claim you do but you really, really, really don't! Just soft bashing.

How do I know this? My old father is a doctor, and I have four nurses in my family + a lot of old colleagues in medicine. There are NO LIVER ISSUES TO WORRY ABOUT.

Some advice - go talk to your local doctor(s) and get the truth from them, don't trust me or PoorOpinion. Ask educated people. Or get an education yourselves.

DO NOT TRUST THE BASHING SNAKES WHO JUST WANT YOU TO DROP YOUR SHARES FOR CHEAP.

(I have had my issues with the board nazis here who have labeled me as a soft basher - I am not.
I really think SeargentSanders is full of sh*t when it comes to labeling others who want to discuss Antibe, but I will give him this - he is right about ATE, this IS a winner who will give dollars per share. )
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities